Al
Alexion (AZN)
Boston MAFounded 19923,500 employees
Private CapbiotechAcquiredRare DiseaseHematologyNephrology
Platform: Complement C5
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Tixatuximab | ALE-6251 | Phase 2 | 1 | Tau | GAOvarian Ca | ||
| ALE-8045 | ALE-8045 | Phase 1 | 2 | FXIa | MGMDD | ||
| ALE-9377 | ALE-9377 | Approved | 4 | CD19 | GAHCC | ||
| Bemazanubrutinib | ALE-8914 | Phase 2/3 | 1 | AuroraA | MyelofibrosisIgAN |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)